Description

KPV (Lys‑Pro‑Val)

Description

• KPV is a naturally derived anti‑inflammatory tripeptide (lysine‑proline‑valine) originally identified as a metabolite of alpha‑melanocyte‑stimulating hormone (alpha‑MSH).
• Investigational ingredient studied for topical and experimental uses to reduce inflammation and support tissue healing.

Key benefits (research findings)

• Exhibits anti‑inflammatory activity by modulating cytokine release and immune cell responses in preclinical studies.
• May promote wound healing and reduce local inflammatory damage in skin and mucosal tissues.
• Shows potential antimicrobial and barrier‑supporting effects in some experimental models.
• Acts locally with limited systemic immune stimulation in topical applications studied.

Primary uses

• Investigational topical applications for inflammatory skin conditions, minor wounds, dermatitis, and mucosal inflammation in preclinical and early clinical research.
• Tool compound in research probing anti‑inflammatory pathways, innate immunity modulation, and tissue repair mechanisms..

Suggested use

• Typically formulated for topical delivery (creams, gels, ointments) at concentrations defined by preclinical/clinical protocols; dosing and frequency vary by formulation and indication.
• Follow product‑specific instructions, clinician guidance, or research protocol. Patch‑test new formulations to check for local sensitivity.
• For investigational or clinical use, adhere to trial protocols and regulatory guidance.

Safety and storage

• Human safety data are limited; generally well tolerated in topical research but allergic reactions or local irritation are possible.
• Avoid systemic use unless in approved clinical trials; safety, tolerability, and pharmacokinetics for systemic administration are not established.
• Handle per supplier/MSDS guidance: use PPE to avoid accidental exposure, and dispose of per institutional protocols.
• Store as recommended by manufacturer (often refrigerated or frozen in lyophilized form); protect from moisture and repeated freeze–thaw cycles after reconstitution.

Quick facts

• Origin: tripeptide fragment of alpha‑MSH with localized anti‑inflammatory properties.
• Status: investigational/preclinical for many indications; regulatory approval and clinical evidence vary by region and indication.
• Not a replacement for medical treatment of serious infections or inflammatory diseases—consult qualified healthcare professionals for clinical care.

Research Use Only Disclaimer

Products sold by SoCo Peptides are intended strictly for laboratory research purposes only.

These compounds are not intended for human consumption, veterinary use, household use, cosmetic use, or therapeutic application. They are not drugs, foods, or dietary supplements and have not been evaluated or approved by the FDA.

By purchasing from this website, the customer represents that they are a qualified researcher or laboratory professional and understand the risks associated with handling research materials.

All products must be handled by trained professionals in appropriate research facilities and in accordance with all applicable laws and regulations.

SoCo Peptides makes no guarantees or claims regarding safety, effectiveness, or medical benefit.